RxDoctor Payments Data

Raul Zayas, MD

Family Medicine · El Paso, TXNPI 1942252549

Payments from drug & device makers

$1,576in general payments, 2019–2025

Across 98 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$240
  • Merck$131
  • Amarin Pharma, Inc.$127
  • GSK$111
  • Pfizer$107
  • Biohaven Pharmaceuticals, Inc.$77
  • plus $782 from 23 others

What the payments were for

  • Food & beverage$1,56099%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,576 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$60,666
Medicare patients
115
Services billed
2,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol280$308,084
TrulicityDulaglutide158$239,682
OzempicSemaglutide164$200,676
MounjaroTirzepatide67$95,744
JardianceEmpagliflozin72$82,431
JanuviaSitagliptin Phosphate51$71,140
VascepaIcosapent Ethyl83$63,230
ForteoTeriparatide12$59,921
ProliaDenosumab32$57,248
EliquisApixaban39$44,640
Humalog Kwikpen U-200Insulin Lispro29$26,951
XareltoRivaroxaban18$23,189
MyrbetriqMirabegron26$23,088
RybelsusSemaglutide15$21,838
Tresiba Flextouch U-100Insulin Degludec28$17,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Forteo$240$395,347237 claims
AstraZenecaFarxiga, Symbicort$30$312,419298 claims
Novo NordiskOzempic, Rybelsus$69$222,514179 claims
Boehringer IngelheimJardiance, Tradjenta$49$98,98384 claims
MerckJanuvia$131$71,14051 claims
AmgenProlia$21$57,24832 claims
PfizerEliquis$107$44,64039 claims
GSKTrelegy Ellipta$111$15,15423 claims
AbbVieSynthroid$38$2,46521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →